The global fertility test market is expected to grow at a CAGR of around 7.3% from 2020 to 2027 and expected to reach the market value of around US$ 720.5 Mn by 2027.
Fertility refers to the ability to conceive and bear a child. Pregnancy begins with the fertilization of an egg by a sperm cell, but male and female bodies must go through several steps before a healthy pregnancy is possible. Infertility affects men and women equally, according to the American Society for Reproductive Medicine, so both partners should be tested. Fertility testing to determine the cause of infertility in women may entail a medical history discussion, blood tests, and minimally invasive procedures. When testing fails to reveal a specific cause, the diagnosis is "unexplained infertility," which affects 15 to 30% of infertile couples, according to the National Institutes of Health.
New developments in fertility testing market
According to a report published by the American Association for the Advancement of Science (AAAS), researchers at Ben-Gurion University of the Negev (BGU) are working on a new, single-dose treatment that may improve both male and female fertility. The new treatment increases the expression of telomerase, the enzyme responsible for the maintenance of DNA sequences at the tip of a chromosome (called telomeres), that affect cell lifespan and contribute to infertility. The novel treatment re-elongates telomeres and protects cells from damage, increasing cell viability and increasing the chances of fertilization, embryo generation, and implantation. The treatment is given in a single dose and wears off within 24 hours. The compound was tested on mice and found to have no toxic effects. The compound also showed a protective effect on the ovaries and testes of mice exposed to radiation, implying that it may be able to protect and improve fertility in women and men undergoing cancer radiation therapy.
"Assisted Reproductive Technologies" best option for fertility testing
Age-related infertility is becoming more common in today's society because, for a variety of reasons, many women wait until their 30s to start families. According to the ASRM, American Society for Reproductive Medicine, a woman's best reproductive years are in her 20s. Fertility gradually declines in the 30s, especially after the age of 35. A healthy, fertile 30-year-old woman has a 20% chance of becoming pregnant each month she tries. By the age of 40, a woman's chance is less than 5% per cycle, which means that less than 5 out of every 100 women are expected to be successful each month. If an underlying cause of infertility is discovered, the clinical care provider may recommend a specific treatment. Advanced infertility therapies such as super ovulation with timed intrauterine insemination (SO/IUI) or in vitro fertilization (IVF) may be recommended in cases of unexplained infertility or when traditional treatments have failed. In women over the age of 40, the success rate of SO/IUI is typically less than 5%. This compares to a success rate of around 10% for women aged 35 to 40. IVF is more effective, but it also has relatively low success rates in women over 40, typically less than 20% per cycle.
COVID-19 impact on fertility testing market
According to the BRITISH COLUMBIA MEDICAL JOURNAL, unlike viruses like rubella, chickenpox, or the Zika virus, there is no evidence that COVID-19 causes birth defects. Expectant mothers who become infected with COVID-19 must be closely monitored due to the immunosuppression and increased respiratory demands of pregnancy. COVID-19 in pregnancy can increase the risk of preterm birth and growth restriction in the baby. In a study of 38 men with COVID-19 in China, 15.8% had detectable virus in their sperm. Furthermore, preliminary evidence suggested that COVID-19 did not pass from mother to child before birth. However, a recent case in the United States discovered evidence of in uterus transmission, but the risk of neonatal infection remains very low, at less than 2%.
The global fertility testing market is segmented based on mode of purchase, product, application, and end-user. Based on mode of purchase, the market is segregated as direct/prescription-based products, OTC-based products, and online products. By product, the market is segmented as ovulation prediction kits, fertility monitors, and male fertility testing products. By application, the market is classified into female fertility products and male fertility products. Further, end-user is segmented as home care settings, hospitals and fertility clinics, and other end users.
The OTC segment accounts for the majority of the global fertility testing market in terms of mode of purchase. OTC dominated the market in the past and will continue to do so during the forecast period. This is due to patients' preference for self-monitoring of healthcare conditions, increased initiatives by market players to raise fertility awareness, and a growing preference for confidentiality and accessibility of test results.
By product, the ovulation prediction kits segment will account for the greatest share of the global fertility testing market. The ovulation prediction kits segment has a large share due to their increasing use, easy over-the-counter availability and low cost, and higher accuracy than natural fertility testing techniques such as calendar methods and cervical mucus monitoring.
Female fertility testing accounts for the largest share of the global fertility testing market and will continue to do so throughout the forecast period. This is due to declining female fertility rates, the availability of a variety of fertility testing options for females, an increase in gynecological issues in women (such as PCOD/PCOS), and the high cost of IVF procedures.
According to end-user, the home care settings segment is expected to grow at the fastest rate in the coming years. This segment's large share and rapid growth can be attributed to patients' preference for self-monitoring of healthcare conditions, easy access to fertility and ovulation monitors on e-commerce websites, the availability of user-friendly and easy-to-handle devices, and the growing preference for test result confidentiality.
North America dominates; Asia Pacific registers fastest growing CAGR for the fertility testing market
The North America province, which includes major countries such as Canada and the United States, accounts for the largest share of the fertility testing market. This is due to factors such as the high prevalence of infertility, increased awareness of fertility testing among women, the increasing age of first-time pregnancies in women, and the easy availability of ovulation and fertility monitors via e-commerce websites.
On the other hand, Asia Pacific will have the fastest growing CAGR in the fertility testing market in the coming years. This is due to an increase in the number of women suffering from lifestyle disorders, increased funding/investment in the development of fertility and ovulation monitors, and a growing focus on the Asia Pacific fertility test market by both international and domestic players.
The prominent players of the global fertility testing market involve Swiss Precision Diagnostics GmbH, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., bioZhena Corporation., Fairhaven Health, Geratherm Medical, Mira, and among others
Market By Mode of Purchase
Market By Product
Ovulation Prediction Kits
Male Fertility Testing Products
Market By Application
Female Fertility Products
Male Fertility Products
Market By End User
Home Care Settings
Hospitals and Fertility Clinics
Other End Users
Fertility test market is expected to reach a market value of around US$ 720.5 Mn by 2027.
The fertility test market is expected to grow at a CAGR of around 7.3% from 2020 to 2027.
Based on mode of purchase, OTC-based products segment is the leading segment in the overall market.
Assisted reproductive technologies best option for fertility testing is one of the prominent factors that drive the demand for fertility test market.
Swiss Precision Diagnostics GmbH, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., bioZhena Corporation., Fairhaven Health, Geratherm Medical, Mira, and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years